RAF modulators and methods of use.

Area of Science:

• Medicinal Chemistry
• Oncology
• Biochemistry

Background:

• RAF kinases are crucial regulators of cellular signaling pathways.
• Dysregulation of RAF kinase activity is implicated in various cancers.
• Targeting RAF kinases represents a significant therapeutic strategy in oncology.

Purpose of the Study:

• To report novel RAF kinase inhibitors developed by Exelixis.
• To characterize the chemical structure and inhibitory potential of new compounds.
• To explore the therapeutic potential of these inhibitors in cancer treatment.

Main Methods:

• Synthesis of a series of compounds featuring a 3-oxo-2,3-dihydro-1H-isoindol-1-yl core.
• Biochemical assays to determine inhibitory concentrations (IC50) against RAF kinases.
• Evaluation of the potential therapeutic applications in relevant disease models.

Main Results:

• Exelixis identified novel chemical matter targeting RAF kinases.
• Many exemplified compounds demonstrated potent inhibition with IC50 values below 100 nM.
• The identified compounds represent a new class of potential anti-cancer agents for Exelixis.

Conclusions:

• The novel 3-oxo-2,3-dihydro-1H-isoindol-1-yl core represents a promising scaffold for RAF kinase inhibitor development.
• These potent inhibitors hold potential for treating cancers characterized by aberrant cellular proliferation.
• This discovery expands Exelixis's portfolio of targeted cancer therapies.